First success for the partnership in the Bristol-Myers Squibb – Teva case

The Judicial Court of Paris has rejected Teva's requests to invalidate a patent and a Supplementary Protection Certificate (SPC) held by Bristol-Myers Squibb, which protect the active ingredient apixaban.

This case represents a new milestone in the fruitful collaboration that has united Gide and Regimbeau for many years in the field of patent litigation. It also marks the very first achievement of our alliance since the official launch of the partnership a few weeks ago.

Apixaban is a molecule developed as a direct oral anticoagulant, a factor Xa inhibitor which forms the basis of the successful drug Eliquis®. Healthcare professionals use this drug to treat and prevent blood clots.

Bristol Myers Squibb is an internationally renowned biopharmaceutical company, with a particularly strong industrial base and R&D investment in France.